Human immunodeficiency virus type 1 clade C antigens (HIV-1 clade C antigens)

Human immunodeficiency virus type 1 (HIV-1) clade C antigens represent the structural and regulatory proteins derived from the most prevalent subtype of HIV-1 globally, particularly dominant in Southern Africa, India, and Ethiopia (Source: PubMed, PMID: 31110112). These antigens, which include the envelope glycoprotein (Env), Gag, Pol, and various accessory proteins, are the primary targets for vaccine development and broadly neutralizing antibodies (bNAbs) due to their essential roles in the viral life cycle, such as host cell attachment and membrane fusion (Source: NIH, NIAID). The high genetic diversity of clade C, especially within the Env region, presents a significant challenge for eliciting broad protection, necessitating the use of clade-specific or multivalent immunogens in clinical trials (Source: Lancet HIV, 2020). Therapeutic strategies targeting these antigens aim to induce robust T-cell responses or provide passive immunity through monoclonal antibodies to control viral replication and prevent the progression to AIDS (Source: Nature Medicine, PMID: 30242149).

Other names

HIV-1 subtype C antigensHIV-1 group M subtype C proteinsHIV-1 clade C envelope proteinsHIV-1 clade C Gag-Pol-Env

Vaccine antigens induce humoral and cellular immune responses, including the production of neutralizing antibodies and T-cell activation, to prevent viral entry or clear infected cells. Monoclonal antibodies bind to specific epitopes on the envelope glycoprotein (gp120/gp41) to neutralize the virus and prevent infection of CD4+ T cells.